Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $55.83 million. The enterprise value is $48.91 million.

Market Cap	55.83M
Enterprise Value	48.91M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025, after market close.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Cue Biopharma has 75.35 million shares outstanding. The number of shares has increased by 33.15% in one year.

Current Share Class	75.35M
Shares Outstanding	75.35M
Shares Change (YoY)	+33.15%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.35%
Owned by Institutions (%)	16.63%
Float	75.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.13
Forward PS	n/a
PB Ratio	6.16
P/TBV Ratio	8.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	6.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 1.08.

Current Ratio	1.03
Quick Ratio	0.91
Debt / Equity	1.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-60.36

Financial Efficiency

Return on equity (ROE) is -221.66% and return on invested capital (ROIC) is -90.82%.

Return on Equity (ROE)	-221.66%
Return on Assets (ROA)	-67.62%
Return on Invested Capital (ROIC)	-90.82%
Return on Capital Employed (ROCE)	-610.18%
Revenue Per Employee	$194,902
Profits Per Employee	-$989,854
Employee Count	41
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.30% in the last 52 weeks. The beta is 1.42, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.42
52-Week Price Change	-46.30%
50-Day Moving Average	0.71
200-Day Moving Average	1.03
Relative Strength Index (RSI)	56.64
Average Volume (20 Days)	276,166

Short Selling Information

The latest short interest is 831,592, so 1.10% of the outstanding shares have been sold short.

Short Interest	831,592
Short Previous Month	774,133
Short % of Shares Out	1.10%
Short % of Float	1.11%
Short Ratio (days to cover)	4.98

Income Statement

In the last 12 months, Cue Biopharma had revenue of $7.99 million and -$40.58 million in losses. Loss per share was -$0.65.

Revenue	7.99M
Gross Profit	-26.65M
Operating Income	-41.22M
Pretax Income	-49.97M
Net Income	-40.58M
EBITDA	-40.83M
EBIT	-41.22M
Loss Per Share	-$0.65

Full Income Statement

Balance Sheet

The company has $14.05 million in cash and $7.13 million in debt, giving a net cash position of $6.92 million or $0.09 per share.

Cash & Cash Equivalents	14.05M
Total Debt	7.13M
Net Cash	6.92M
Net Cash Per Share	$0.09
Equity (Book Value)	6.58M
Book Value Per Share	0.11
Working Capital	433,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$34.72 million and capital expenditures -$161,000, giving a free cash flow of -$34.88 million.

Operating Cash Flow	-34.72M
Capital Expenditures	-161,000
Free Cash Flow	-34.88M
FCF Per Share	-$0.46

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-515.88%
Pretax Margin	-507.87%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-33.15%
Shareholder Yield	-33.15%
Earnings Yield	-72.69%
FCF Yield	-62.47%

Analyst Forecast

The average price target for Cue Biopharma is $3.00, which is 304.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.00
Price Target Difference	304.86%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	101.22%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cue Biopharma has an Altman Z-Score of -25.42 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-25.42
Piotroski F-Score	3